Remove 2019 Remove Documentation Remove Pharmaceutical Companies
article thumbnail

Ex-Merck & Co scientist accused of stealing trade secrets could face jail

pharmaphorum

In a document outlining the charges against Shafat Quadri, of North Potomac, Maryland the US Department of Justice (DoJ) referred only to “one of the largest pharmaceutical companies in the world” based in New Jersey.

article thumbnail

Time to change the channel? The future for customer engagement models

pharmaphorum

The pandemic has triggered a change in how pharmaceutical companies are engaging with healthcare professionals. When IQVIA polled non COVID-19 treating Italian HCPs in March when the crisis was at its worst, it asked HCPs if they still welcomed pharmaceutical company engagement during the crisis. The answer was yes.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Stay calm and carry on: How to implement the updated ABPI code

pharmaphorum

The updated Association of the British Pharmaceutical Industry ( ABPI ) Code of Practice was agreed at the body’s general meeting in January, following months of public consultation. While the foundations remain the same, the updated code, which comes into force on 1 July, is structured differently to the 2019 version.

article thumbnail

Increasing patient engagement with UK clinical trials

pharmaphorum

Pharmaceutical companies often struggle to actively involve patients in the design phase of clinical trials but doing so can have huge benefits for the sustainability and success of research. In 2014 Keith was fortunate to become a full-time salaried patient research ambassador at Liverpool Heart and Chest Hospital Trust.

article thumbnail

GAMP 5 update: computerized system expectations for pharma manufacturers

European Pharmaceutical Review

Validation projects have often been documentation-focused exercises, more befitting a grammar exercise than artifacts supportive of regulated activity. The GAMP 5 Second Edition guide emphasises that focus should be on value-adding activities rather than documentation for documentation’s sake.”

article thumbnail

Using RWE in rare disease drug development: effective innovations with historical controls

European Pharmaceutical Review

11 have recently conducted an analysis of international HTA submissions from 2011-2019 to determine the acceptability of single arm clinical studies and ECs as part of the drug reimbursement process. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE. Patel et al.

article thumbnail

Navigating Life Sciences Construction in California

ISPE

billion in 2019 to $17.3 It's no wonder that global pharmaceutical companies are increasingly sourcing innovation through alliances and partnerships with their peers in California. The sub-standard heights were discovered during the initial document review and site assessment. billion in 2022.